These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 18685606)

  • 1. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME; Epstein BJ
    J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of calcium channel blockers in cardiovascular risk reduction: issues in Latin America.
    Alcocer L; Bendersky M; Acosta J; Urina-Triana M
    Am J Cardiovasc Drugs; 2010; 10(3):143-54. PubMed ID: 20524716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension.
    Swales P; Williams B
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):79-89. PubMed ID: 12228847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
    Mizuno Y; Jacob RF; Mason RP
    Am J Hypertens; 2008 Oct; 21(10):1076-85. PubMed ID: 18756260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
    Schmieder RE
    Clin Exp Hypertens; 2010 Jan; 32(1):35-42. PubMed ID: 20144071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive blood pressure control and stroke prevention: role of calcium channel blockers.
    Papadopoulos DP; Papademetriou V
    J Hypertens; 2008 May; 26(5):844-52. PubMed ID: 18398322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
    Cohn JN; Goldman JM
    Am J Hypertens; 2008 Mar; 21(3):248-56. PubMed ID: 18219303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
    White WB
    Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
    Bramlage P
    Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On target to dual block RAS?
    Papadopoulos DP; Papademetriou V; Makris TK
    Angiology; 2009 Dec-2010 Jan; 60(6):739-49. PubMed ID: 19144653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin system modulation: the weight of evidence.
    Brown B; Hall AS
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.